JPWO2020198064A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020198064A5
JPWO2020198064A5 JP2021557075A JP2021557075A JPWO2020198064A5 JP WO2020198064 A5 JPWO2020198064 A5 JP WO2020198064A5 JP 2021557075 A JP2021557075 A JP 2021557075A JP 2021557075 A JP2021557075 A JP 2021557075A JP WO2020198064 A5 JPWO2020198064 A5 JP WO2020198064A5
Authority
JP
Japan
Prior art keywords
ophthalmic solution
hours
less
day
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526917A (ja
JP7706758B2 (ja
JP2022526917A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/024022 external-priority patent/WO2020198064A1/en
Publication of JP2022526917A publication Critical patent/JP2022526917A/ja
Publication of JPWO2020198064A5 publication Critical patent/JPWO2020198064A5/ja
Publication of JP2022526917A5 publication Critical patent/JP2022526917A5/ja
Priority to JP2025013851A priority Critical patent/JP2025061972A/ja
Application granted granted Critical
Publication of JP7706758B2 publication Critical patent/JP7706758B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557075A 2019-03-26 2020-03-20 眼科用製剤およびその使用 Active JP7706758B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013851A JP2025061972A (ja) 2019-03-26 2025-01-30 眼科用製剤およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962824233P 2019-03-26 2019-03-26
US62/824,233 2019-03-26
US201962857874P 2019-06-06 2019-06-06
US62/857,874 2019-06-06
PCT/US2020/024022 WO2020198064A1 (en) 2019-03-26 2020-03-20 Ophthalmic formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013851A Division JP2025061972A (ja) 2019-03-26 2025-01-30 眼科用製剤およびその使用

Publications (4)

Publication Number Publication Date
JP2022526917A JP2022526917A (ja) 2022-05-27
JPWO2020198064A5 true JPWO2020198064A5 (https=) 2023-03-28
JP2022526917A5 JP2022526917A5 (https=) 2023-03-28
JP7706758B2 JP7706758B2 (ja) 2025-07-14

Family

ID=72611748

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557075A Active JP7706758B2 (ja) 2019-03-26 2020-03-20 眼科用製剤およびその使用
JP2025013851A Pending JP2025061972A (ja) 2019-03-26 2025-01-30 眼科用製剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013851A Pending JP2025061972A (ja) 2019-03-26 2025-01-30 眼科用製剤およびその使用

Country Status (3)

Country Link
US (2) US11786518B2 (https=)
JP (2) JP7706758B2 (https=)
WO (1) WO2020198064A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス, インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3856478A4 (en) 2018-09-25 2022-06-08 Aldeyra Therapeutics, Inc. FORMULATIONS FOR THE TREATMENT OF DRY EYE
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
US20220211691A1 (en) * 2021-01-07 2022-07-07 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
WO2022150580A1 (en) * 2021-01-07 2022-07-14 Aldeyra Therapeutics, Inc. Treatment of dry eye disease

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
JPS6192592A (ja) 1984-10-12 1986-05-10 Norin Suisansyo Shokuhin Sogo Kenkyusho 分岐サイクロデキストリンの製造方法
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU8942491A (en) 1990-10-22 1992-05-20 Bausch & Lomb Incorporated Method and composition for cleaning contact lenses
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
JP2746832B2 (ja) 1993-05-14 1998-05-06 大鵬薬品工業株式会社 眼局所抗アレルギー剤
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
FR2742053B1 (fr) 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6492520B1 (en) 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
WO1998050372A1 (de) 1997-05-02 1998-11-12 Schering Aktiengesellschaft Substituierte heterocyclen und deren verwendung in arzneimitteln
EP1012151B1 (en) 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
JP3568108B2 (ja) 1999-07-28 2004-09-22 松下電器産業株式会社 デジタル地図の位置情報伝達方法とそれを実施する装置
AU1735001A (en) 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
JP4748289B2 (ja) 2000-06-23 2011-08-17 ライオン株式会社 点眼剤、眼科用組成物及び吸着抑制方法
WO2004069157A2 (en) 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
EP2301549A1 (en) 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
JP2005132834A (ja) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
KR20060109947A (ko) 2003-11-20 2006-10-23 오쎄라 파마슈티걸즈, 인크. 황반 변성 및 다른 안과 질환의 개선
JP2005187407A (ja) 2003-12-25 2005-07-14 Lion Corp アレルギー眼疾患用眼科組成物
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
US8435965B2 (en) 2005-12-27 2013-05-07 Lion Corporation Composition for soft contact lens and adsorption suppressing method
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP4466875B2 (ja) 2006-04-05 2010-05-26 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
JP5194218B2 (ja) 2006-06-05 2013-05-08 株式会社メニコンネクト 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
RU2434630C2 (ru) 2006-08-31 2011-11-27 Юранд, Инк. Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
MX2010003667A (es) 2007-10-05 2010-09-28 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
CN102177157A (zh) 2008-08-12 2011-09-07 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并*唑类、苯并噻唑类和相关的类似物
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
AU2010226249A1 (en) 2009-03-17 2011-10-13 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
WO2010141834A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
EP2477594A4 (en) 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CA2788440A1 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US10463687B2 (en) 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
CN103442735B (zh) 2011-01-31 2016-11-09 特米拉公司 用于减轻技术领域中所不希望的医学状况的有效要素
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
WO2015187942A1 (en) 2014-06-04 2015-12-10 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
EP2916827B1 (en) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
RU2015120478A (ru) 2012-12-20 2017-01-25 Альдейра Терапьютикс, Инк. Пери-карбинолы
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
SG11201505599YA (en) 2013-01-25 2015-08-28 Aldeyra Therapeutics Inc Novel traps in the treatment of macular degeneration
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
WO2016085939A2 (en) 2014-11-24 2016-06-02 Case Western Reserve University Compounds and methods of treating ocular disorders
KR20180073553A (ko) 2015-08-21 2018-07-02 알데이라 테라퓨틱스, 아이엔씨. 알데히드 접합체 및 이의 용도
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
CA3016759A1 (en) * 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
AU2017317529A1 (en) 2016-08-22 2019-02-21 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
JP2019532029A (ja) 2016-08-22 2019-11-07 アルデイラ セラピューティクス, インコーポレイテッド アルデヒド補足化合物およびその使用
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
MX2019010576A (es) 2017-03-16 2019-10-07 Aldeyra Therapeutics Inc Compuestos polimorficos y usos de los mismos.
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス, インコーポレイテッド 炎症性障害の処置
WO2020018498A1 (en) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
WO2020028820A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3856478A4 (en) 2018-09-25 2022-06-08 Aldeyra Therapeutics, Inc. FORMULATIONS FOR THE TREATMENT OF DRY EYE
WO2020072621A1 (en) 2018-10-02 2020-04-09 Aldeyra Therapeutics, Inc. Contact lens solutions and kits
JP2022511030A (ja) 2018-12-05 2022-01-28 アルデイラ セラピューティクス, インコーポレイテッド 注射可能な製剤
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
WO2021195211A1 (en) 2020-03-24 2021-09-30 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
EP4135697A4 (en) 2020-04-13 2024-05-15 Aldeyra Therapeutics, Inc. Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
US20230228744A1 (en) 2020-06-04 2023-07-20 Aldeyra Therapeutics, Inc. Dry eye disease biomarkers and their use for treatment
US20220211691A1 (en) 2021-01-07 2022-07-07 Aldeyra Therapeutics, Inc. Treatment of dry eye disease

Similar Documents

Publication Publication Date Title
JPWO2020198064A5 (https=)
JP7706758B2 (ja) 眼科用製剤およびその使用
WO2008005819A2 (en) Ophthalmic formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP7505786B2 (ja) ドライアイ疾患を処置するための製剤
JP4130358B2 (ja) メトロニダゾール含有ゲル組成物
US5021404A (en) Angiostatic collagen modulators
JP2014515355A (ja) 高濃度オロパタジンの眼用組成物
WO2002089815A2 (en) Disinfecting and solubilizing steroid compositions
AU2002308544A1 (en) Disinfecting and solubilizing steroid compositions
Soliman et al. Potential use of cyclodextrin complexes for enhanced stability, anti-inflammatory efficacy, and ocular bioavailability of loteprednol etabonate
JP7716996B2 (ja) 薬剤を含む水性組成物のpHを安定化させるための方法
CN101410123A (zh) 低剂量的双氯芬酸和β-环糊精的制剂
CN101663039B (zh) 壳聚糖提高指甲生长速率的用途
CN119451680A (zh) 包含美洛昔康的药物组合物
EP2547340A2 (en) Ophthalmic formulations of cetirizine and methods of use
US20120022019A1 (en) Medicinal Steroids Cream And A Process To Make It
CN111727035A (zh) 包含比拉斯汀、β-环糊精和至少一种胶凝剂的眼用组合物
Holbrook et al. Aqueous hydrocortisone mouthwash solution: clinical evaluation
CN111225687A (zh) 用于治疗眼科疾患的方法和组合物
JP2001055335A (ja) アレルギー性皮膚疾患治療剤
WO2003101460A1 (en) External preparations for treating dermatitis
KR0181763B1 (ko) 피부염의 치료외용제
JP2017503029A (ja) ブデソニドシクロデキストリン処方物
WO2010109423A1 (en) A medicinal antifungal and steroids cream comprising chitosan and a process to make it
TWI801053B (zh) 眼用組合物